Nucala

Active Ingredient(s): Mepolizumab
FDA Approved: * November 4, 2015
Pharm Company: * GLAXOSMITHKLINE LLC
Category: Asthma

Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES).[3] It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system. The most common side effects include headache, injection site reactions, and back pain.[2] Contents 1 Medical uses 2 Side effects 3 Overdose 4 Interactions 5 Pharmacol... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Nucala 100 mg/ml Subcutaneous Injection, Solution

NDC: 0173-0892

Labeler:

Glaxosmithkline LLC

Nucala 40 mg/.4ml Subcutaneous Injection, Solution

NDC: 0173-0904

Labeler:

Glaxosmithkline LLC

Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution

NDC: 12064-018

Labeler:

Glaxosmithkline Manufacturing Spa